Payload ID	PAY0WQPKG
Name	B19
Synonyms	B19    Click to Show/Hide
Target	Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)					Target Info
Structure
	3D MOL			2D MOL
Formula	C29H34ClN5O5
Isosmiles	O=C1C(C=CC(CNC(NC(C=C2)=CC(Cl)=C2CCCOC3CNCCC3)=O)=C4)=C4CN1C(CCC5=O)C(N5)=O
InChI	InChI=1S/C29H34ClN5O5/c30-24-14-21(7-6-19(24)3-2-12-40-22-4-1-11-31-16-22)33-29(39)32-15-18-5-8-23-20(13-18)17-35(28(23)38)25-9-10-26(36)34-27(25)37/h5-8,13-14,22,25,31H,1-4,9-12,15-17H2,(H2,32,33,39)(H,34,36,37)
InChIKey	AUCAGMGHZBLJIS-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight		568.074	Polar area		128.87
	Complexity		1246.794577	xlogp Value		3.1239
	Heavy Count		40	Rot Bonds		9
	Hbond acc		6	Hbond Donor		4

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half maximal inhibitory Concentration (lC50)	<10	nM	Ramos cells	Burkitt lymphoma	CVCL_0597	[1]
Half maximal inhibitory Concentration (lC50)	<10	nM	Ramos cells	Burkitt lymphoma	CVCL_0597	[1]
Half maximal inhibitory Concentration (lC50)	<10	nM	HL-60 cells	Adult acute myeloid leukemia	CVCL_0002	[1]
Half maximal inhibitory Concentration (lC50)	<10	nM	HL-60 cells	Adult acute myeloid leukemia	CVCL_0002	[1]
Half maximal inhibitory Concentration (lC50)	<10	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[1]
Half maximal inhibitory Concentration (lC50)	<10	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[1]
Half maximal inhibitory Concentration (lC50)	<10	nM	NCI-H929 cells	Plasma cell myeloma	CVCL_1600	[1]
Half maximal inhibitory Concentration (lC50)	<10	nM	NCI-H929 cells	Plasma cell myeloma	CVCL_1600	[1]
Half maximal inhibitory Concentration (lC50)	10-50	nM	NCI-H82 cells	Lung small cell carcinoma	CVCL_1591	[1]
Half maximal inhibitory Concentration (lC50)	10-50	nM	NCI-H82 cells	Lung small cell carcinoma	CVCL_1591	[1]
Half maximal Degradation Concentration (DC50)	15.96	nM	HibiT-GSPT1 HEK293T cells	Normal	CVCL_0063	[1]
Half maximal Degradation Concentration (DC50)	15.96	nM	HibiT-GSPT1 HEK293T cells	Normal	CVCL_0063	[1]
Half maximal inhibitory Concentration (lC50)	200-1000	nM	HCT-15 cells	Colon adenocarcinoma	CVCL_0292	[1]
Half maximal inhibitory Concentration (lC50)	200-1000	nM	HCT-15 cells	Colon adenocarcinoma	CVCL_0292	[1]
Half maximal inhibitory Concentration (lC50)	3.2616	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[1]
Half maximal inhibitory Concentration (lC50)	3.2616	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[1]
Half maximal inhibitory Concentration (lC50)	<50	nM	SNU-5 cells	Gastric adenocarcinoma	CVCL_0078	[1]
Half maximal inhibitory Concentration (lC50)	<50	nM	SNU-5 cells	Gastric adenocarcinoma	CVCL_0078	[1]
Half maximal inhibitory Concentration (lC50)	50-200	nM	AsPc-1 cells	Pancreatic ductal adenocarcinoma	CVCL_0152	[1]
Half maximal inhibitory Concentration (lC50)	50-200	nM	AsPc-1 cells	Pancreatic ductal adenocarcinoma	CVCL_0152	[1]

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 15 pM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15-25 pM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0001949 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to BT-474 cells
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03135 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.6134 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to NCI-N87 cells
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.838 nM	Low HER2 expression (HER2+)
Method Description	Cytotoxicity of ADC to T47D cells
In Vitro Model	Invasive breast carcinoma of no special type	T47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.003352 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.003748 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to BT-474 cells
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.01296 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.175 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to NCI-N87 cells
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.02 nM	Low HER2 expression (HER2+)
Method Description	Cytotoxicity of ADC to T47D cells
In Vitro Model	Invasive breast carcinoma of no special type	T47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.005559 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to BT-474 cells
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.01479 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.3965 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to NCI-N87 cells
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.064 nM	Low HER2 expression (HER2+)
Method Description	Cytotoxicity of ADC to T47D cells
In Vitro Model	Invasive breast carcinoma of no special type	T47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0089 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.01116 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0179 nM	High HER2 expression (HER2+++)
Method Description	Cytotoxicity of ADC to SK-BR-3 cells
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0227 nM	High DLL3 expression (DLL3+++)
Method Description	Cytotoxicity of ADC to NCI-H82 cells
In Vitro Model	Lung small cell carcinoma	NCI-H82 cells		CVCL_1591

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.06064 nM	High DLL3 expression (DLL3+++)
Method Description	Cytotoxicity of ADC to NCI-H82 cells
In Vitro Model	Lung small cell carcinoma	NCI-H82 cells		CVCL_1591

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.06538 nM	High BCMA expression (BCMA+++)
Method Description	Cytotoxicity of ADC to NCI-H929 cells
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.07176 nM	High BCMA expression (BCMA+++)
Method Description	Cytotoxicity of ADC to NCI-H929 cells
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.118 nM	High DLL3 expression (DLL3+++)
Method Description	Cytotoxicity of ADC to NCI-H82 cells
In Vitro Model	Lung small cell carcinoma	NCI-H82 cells		CVCL_1591

Ref 1	Antibody-drug conjugate
Ref 2	Domide molecular glue derivative and use thereof